Erratum: Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways (STEM CELLS (2007) 25 (2845) DOI: 10.1634/stemcells.2007-0065);Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways

Stem Cells

Volumn 25, Issue 11, 2007, Pages 2845-2854

  Manton, Kerry J ^a   Leong, Denise F M ^a   Cool, Simon M ^a,b   Nurcombe, Victor ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chondroitinase; Heparinase; Mesenchymal stem cell; Osteoblast; Wnts

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; LYMPHOID ENHANCER FACTOR 1; OSTEOCALCIN; PERLECAN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SYNDECAN; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN;

ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

EID: 36248989688     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2025     Document Type: Erratum

References (54)

1. Iozzo RV. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 1998;67:609-652.
2. Bierbaum S, Douglas T, Hanke T et al. Collageneous matrix coatings on titanium implants modified with decorin and chondroitin sulfate: Characterization and influence on osteoblastic cells. J Biomed Mater Res A 2006;77:551-562.
3. Cool SM, Nurcombe V. The osteoblast-heparan sulfate axis: Control of the bone cell lineage. Int J Biochem Cell Biol 2005;37:1739-1745.
4. Cool SM, Nurcombe V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem 2006;99:1040-1051.
5. Grzesik WJ, Frazier CR, Shapiro JR et al. Age-related changes in human bone proteoglycan structure. Impact of osteogenesis imperfecta. J Biol Chem 2002;277:43638-43647.
6. Jackson RA, McDonald MM, Nurcombe V et al. The use of heparan sulfate to augment fracture repair in a rat fracture model. J Orthop Res 2006;24:636-644.
7. Kang SK, Putnam L, Dufour J et al. Expression of telomerase extends the lifespan and enhances osteogenic differentiation of adipose tissue-derived stromal cells. STEM CELLS 2004;22:1356-1372.
8. Ling L, Murali S, Dombrowski C et al. Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells. J Cell Physiol 2006;209:811-825.
9. Newman P, Bonello F, Wierzbicki AS et al. The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: Role of heparan sulfate proteoglycans and apolipoprotein E. J Bone Miner Res 2002;17:426-433.
10. Nurcombe V, Ford MD, Wildschut JA et al. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 1993;260:103-106.
11. Brickman YG, Ford MD, Gallagher JT et al. Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem 1998;273:4350-4359.
12. Yeo TK, Yeo KT, Wight TN. Differential transport kinetics of chondroitin sulfate and dermatan sulfate proteoglycan by monkey aorta smooth muscle cells. Arch Biochem Biophys 1992;294:9-16.
13. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R et al. Extracellular sequestration and release of fibroblast growth factor: A regulatory mechanism? Trends Biochem Sci 1991;16:268-271.
14. Gallagher JT. Heparan sulfate: Growth control with a restricted sequence menu. J Clin Invest 2001;108:357-361.
15. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001;108:169-173.
16. Jiao X, Billings PC, O'Connell MP et al. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007;282:1080-1086.
17. Engler AJ, Sen S, Sweeney HL et al. Matrix elasticity directs stem cell lineage specification. Cell 2006;126:677-689.
18. McBeath R, Pirone DM, Nelson CM et al. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 2004;6:483-495.
19. Prabhakar V, Capila I, Bosques CJ et al. Chondroitinase ABC I from Proteus vulgaris: Cloning, recombinant expression and active site identification. Biochem J 2005;386:103-112.
20. Pikas DS, Li JP, Vlodavsky I et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998;273:18770-18777.
21. Okada Y, Yamada S, Toyoshima M et al. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 2002;277:42488-42495.
22. Kram V, Zcharia E, Yacoby-Zeevi O et al. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J Cell Physiol 2006;207:784-792.
23. Rodan GA, Noda M. Gene expression in osteoblastic cells. Crit Rev Eukaryot Gene Expr 1991;1:85-98.
24. Sedita J, Izvolsky K, Cardoso WV. Differential expression of heparan sulfate 6-O-sulfotransferase isoforms in the mouse embryo suggests distinctive roles during organogenesis. Dev Dyn 2004;231:782-794.
25. Li X, Liu P, Liu W et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005;37:945-952.
26. Holmen SL, Zylstra CR, Mukherjee A et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005;280:21162-21168.
27. Varki A. Six blind men and the elephant - the many faces of heparan sulfate. Proc Natl Acad Sci U S A 2002;99:543-545.
28. Manton KJ, Sadasivam M, Cool SM et al. Bone-specific heparan sulfates induce osteoblast growth arrest and downregulation of retinoblastoma protein. J Cell Physiol 2006;209:219-229.
29. David G, Bai XM, Van der Schueren B et al. Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol 1992;119:961-975.
30. Reiland J, Sanderson RD, Waguespack M et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: Functional implications for tumor cell invasion. J Biol Chem 2004;279:8047-8055.
31. Oohira A, Matsui F, Watanabe E et al. Developmentally regulated expression of a brain specific species of chondroitin sulfate proteoglycan, neurocan, identified with a monoclonal antibody IG2 in the rat cerebrum. Neuroscience 1994;60:145-157.
32. Deepa SS, Yamada S, Zako M et al. Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor. J Biol Chem 2004;279:37368-37376.
33. Jackson RA, Murali S, van Wijen AJ et al. Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. J Cell Physiol 2007;210:38-50.
34. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005;16:205-213.
35. Hu H, Hilton MJ, Tu X et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005;132:49-60.
36. Jaiswal N, Haynesworth SE, Caplan AI et al. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997;64:295-312.
37. Pratap J, Galindo M, Zaidi SK et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 2003;63:5357-5362.
38. Stein GS, Lian JB, Stein JL et al. Temporal and spatial parameters of skeletal gene expression: Targeting RUNX factors and their coregulatory proteins to subnuclear domains. Connect Tissue Res 2003;44(suppl 1):149-153.
39. Galindo M, Pratap J, Young DW et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 2005;280:20274-20285.
40. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996;237:295-302.
41. Ohkawara B, Iemura S, ten Dijke P et al. Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol 2002;12:205-209.
42. Jackson SM, Nakato H, Sugiura M et al. dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development 1997;124:4113-4120.
43. Grisaru S, Cano-Gauci D, Tee J et al. Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol 2001;231:31-46.
44. Pilia G, Hughes-Benzie RM, MacKenzie A et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241-247.
45. Kreuger J, Perez L, Giraldez AJ et al. Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity. Dev Cell 2004;7:503-512.
46. Kirkpatrick CA, Dimitroff BD, Rawson JM et al. Spatial regulation of Wingless morphogen distribution and signaling by Dally-like protein. Dev Cell 2004;7:513-523.
47. Paine-Saunders S, Viviano BL, Economides AN et al. Heparan sulfate proteoglycans retain Noggin at the cell surface: A potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem 2002;277:2089-2096.
48. Irie A, Habuchi H, Kimata K et al. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 2003;308:858-865.
49. Takada T, Katagiri T, Ifuku M et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 2003;278:43229-43235.
50. Street JT, McGrath M, O'Regan K et al. Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res 2000;381:278-279.
51. Monreal M, Olive A, Lafoz E et al. Heparins, coumarin, and bone density. Lancet 1991;338:706.
52. Capurro MI, Xiang YY, Lobe C et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-6254.
53. Catelas I, Sese N, Wu BM et al. Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro. Tissue Eng 2006;12:2385-2396.
54. Gilbert L, He X, Farmer P et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002;277:2695-2701.